CN114248434B - 3D printing pharmaceutical method with controllable release time - Google Patents

3D printing pharmaceutical method with controllable release time Download PDF

Info

Publication number
CN114248434B
CN114248434B CN202111585179.8A CN202111585179A CN114248434B CN 114248434 B CN114248434 B CN 114248434B CN 202111585179 A CN202111585179 A CN 202111585179A CN 114248434 B CN114248434 B CN 114248434B
Authority
CN
China
Prior art keywords
auxiliary material
release time
drug
release
material layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111585179.8A
Other languages
Chinese (zh)
Other versions
CN114248434A (en
Inventor
阮萍
蔡永铭
冯博华
刘世俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Pharmaceutical University
Original Assignee
Guangdong Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Pharmaceutical University filed Critical Guangdong Pharmaceutical University
Priority to CN202111585179.8A priority Critical patent/CN114248434B/en
Publication of CN114248434A publication Critical patent/CN114248434A/en
Application granted granted Critical
Publication of CN114248434B publication Critical patent/CN114248434B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10—Processes of additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/30—Auxiliary operations or equipment
    • B29C64/386—Data acquisition or data processing for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/30—Auxiliary operations or equipment
    • B29C64/386—Data acquisition or data processing for additive manufacturing
    • B29C64/393—Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y10/00—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y50/00—Data acquisition or data processing for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y50/00—Data acquisition or data processing for additive manufacturing
    • B33Y50/02—Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Optics & Photonics (AREA)
  • Mechanical Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

The invention relates to a 3D printing pharmaceutical method with controllable release time, which comprises the steps of inputting original models of different medicines into a printer, extracting data of auxiliary material layers in the original models of the medicines, and establishing standard release time T of the auxiliary material layers; setting target release time T1 of the drug, selecting an auxiliary material layer with the standard release time T of the auxiliary material layer being closest to T1, wherein the difference between T and T1 is delta T1; if DeltaT 1 is larger than zero, generating a plurality of pores with the volume of S on the auxiliary material layer; if delta T1 is smaller than zero, a plurality of slow-release auxiliary material layers with the thickness of C are regenerated outside the auxiliary material layers. The original drug model is used as an original model, the data of the auxiliary material layer of the original model corresponds to the fixed release time of the drug, and when the release time of the drug needs to be controlled, the model structure of the auxiliary material layer in the original model corresponding to the drug is changed, so that the release time of the drug is controllable. The medicine is not required to be remodelled every time, and the workload of medicine modeling is reduced, so that the cost is reduced.

Description

3D printing pharmaceutical method with controllable release time
Technical Field
The invention relates to the field of pharmaceutical methods, in particular to a 3D printing pharmaceutical method with controllable release time.
Background
The existing pharmaceutical method is that a pharmaceutical factory or a pharmaceutical unit performs mass production, and the disadvantage of the mass production method is that the release time of the produced medicines is fixed within a certain range, and the optimal release time of the medicines after taking the medicines is different from the fixed release time of the medicines because of the own illness of different patients, so that the medicines cannot achieve the optimal treatment effect. And the mass production of medicines cannot realize personalized customization of the release time of medicines according to specific cases.
The existing adult sustained release tablet manufactured by a 3D printing mode comprises a 3D printing multilayer controlled release tablet manufactured by a 3D printer through printing materials, wherein the number of layers of the multilayer controlled release tablet is 3-4, the thickness of the outer layer of the multilayer controlled release tablet is 4-6 mm, the thickness of the inner layer of the multilayer controlled release tablet is 3-4 mm, the concentration of drug carried by the 3D printing multilayer controlled release tablet is lower than that of drug carried by the inner layer, the concentration of drug carried by the 3D printing multilayer controlled release tablet is 0.25, and the concentration ratio of the outer layer to the inner layer is: 1 to 0.55:1. the tablet is slowly released by printing the outer layers with different thicknesses through the slowly releasing control agents with different concentrations.
By using the method, medicines with different release times are required to be input into the 3D printer for printing after being subjected to medicine modeling again each time, so that the workload is high, the cost is high, and the application is difficult to achieve in practice.
Disclosure of Invention
The invention provides a 3D printing pharmaceutical method with controllable release time, which aims to solve the problems of large workload and high cost of drug printing in the prior art, and can print out the drug with controllable release time by only changing the original model parameters of the drug, thereby reducing the workload and the production cost.
In order to solve the technical problems, the invention adopts the following technical scheme: a release time controllable 3D printing pharmaceutical method comprising the steps of:
step one: inputting original models of different medicines into a printer, wherein the original models of the medicines comprise medicinal materials and auxiliary material layers wrapping the medicinal materials; extracting data of an auxiliary material layer in an original model of the medicine, wherein the auxiliary material layer corresponds to the fixed release time of the medicine, and establishing standard release time T of the auxiliary material layer;
step two: setting target release time T1 of the drug, selecting an auxiliary material layer with the standard release time T of the auxiliary material layer closest to T1, wherein the difference between the fixed release time T of the drug and the target release time T1 is DeltaT1=T-T1; if DeltaT 1 is larger than zero, generating a plurality of pores with the volume of S on the auxiliary material layer, wherein each pore correspondingly reduces the release time T, and the number of the pores n 1= DeltaT1/T; if DeltaT 1 is smaller than zero, a plurality of slow-release auxiliary material layers with the thickness of C are regenerated outside the auxiliary material layers, the release time T1 is correspondingly increased for each slow-release auxiliary material layer, and the quantity of the slow-release auxiliary material layers is n 1= DeltaT1/T1; and (3) storing the new pharmaceutical model I after the dosage of the medicine is generated in the auxiliary material layer.
In the above technical scheme, the original mass-produced drug model is used as an original model input to the 3D printer, and the data of the auxiliary material layer of the original model is used to correspond to the fixed release time of the drug, so as to establish a database of the auxiliary material layer standard release time T. Since the original drug release time is often fixed at a time such as 5 minutes, 10 minutes, or 20 minutes. When the release time of the drug is required to be controlled and is not the standard release time, selecting an auxiliary material layer reference according to the target release time T1 and modifying parameters of the auxiliary material layer according to the method of the step two. When different medicines are printed to control the release time, the whole medicine is not required to be remodelled, and only the medicine model with the release time meeting the target requirement can be obtained by modifying the auxiliary material layer of the original model, so that the workload of medicine modeling is reduced.
Preferably, the method further comprises a third step of generating a second drug model based on the first drug model if another target release time T2 of the drug needs to be set. Because the standard release time T of the auxiliary material layer is fixed and the spans are larger, if the same medicine with different release time is modified by taking the original model as the basis, the calculated amount is larger, and if the time difference between the T2 and the T1 is closer, the parameter modification is carried out by taking the medicine model I as the basis, so that the workload of medicine modeling can be further reduced.
Preferably, the target release time T2 of the drug model two is set to be one if T2 is smaller than T1 and T1 is smaller than T; if T2 is greater than T1 and less than T, executing second setting;
setting one: based on the auxiliary material layer of the new model I generated in the step two; printing 1 unit of quick release control agent in the pore, wherein the release time T3 is correspondingly reduced per unit of quick release control agent, and the printing amount of the quick release control agent is n2= (T1-T2)/T3;
setting two: based on the auxiliary material layer of the new model I generated in the step two; printing 1 unit of slow release control agent in the pore, wherein the release time T4 is correspondingly increased per unit of slow release control agent, and the printing amount of the slow release control agent is n2= (T2-T1)/T4;
the release time of the drug is further changed on the basis of the second drug model, since the number of pores that can be formed by the auxiliary layer is limited, since the control of the release time of the drug is achieved by filling the immediate release control agent and the sustained release control agent.
Preferably, multiple layers of sequentially nested auxiliary material layers with sequentially increasing release time are generated according to the second step, medicines are distributed in cavities among the auxiliary material layers, and a multiple-layer nested medicine model III is generated. After the patient swallows the medicine, the release time of the medicine in the human body is different from the set release time of the medicine due to the individual condition difference, for example, the set release time of the medicine is 10 minutes, but the release of the medicine can be completed in less than 10 minutes after the medicine enters the human body, and the release of the medicine can be completed in more than 10 minutes. Thus, by the plurality of auxiliary material layers, wherein the release time of the auxiliary material layer located at the intermediate position is set to the target release time, and the release time of the auxiliary material layer located at the outer layer is set to be shorter than the target release time, the release time of the auxiliary material layer located at the inner layer is set to be longer than the target release time. The medicine between each auxiliary material layer can be released intermittently, and the release time of the medicine is within a certain range so as to cover the target release time. Ensuring that the drug is released at the optimal release time point.
Preferably, according to step three, a multi-layer nested drug model four is generated based on the drug model three. After the medicine model III is stored, when the same medicine printing is needed in the follow-up process but different target release time is needed, the medicine model IV meeting the requirements is built by adopting the method of the step III to change parameters based on the medicine model III, so that the similar medicine printing does not need repeated modeling, and the workload is reduced.
Preferably, different medicinal materials are filled in the cavity between each auxiliary material layer in the third medicinal model and the fourth medicinal model. The tablet can be swallowed to release different medicines at different times, so that the dosage can be reduced.
Preferably, cavities between each auxiliary material layer in the third medicine model and the fourth medicine model are filled with the same medicinal materials and the content of the medicinal materials is equal.
Preferably, a layering printing mode is adopted, and the drug model is printed layer by layer after being divided into a plurality of flat layers. Respectively loading the material of the auxiliary material layer, the medicinal material, the quick release control agent and the slow release control agent on different spray heads, printing the auxiliary material layer when each flat layer is printed, and skipping when the positions of the medicinal material, the quick release control agent and the slow release control agent are needed to be printed; and after printing of the auxiliary material layer of one flat layer, filling the quick release control agent and the slow release control agent if the quick release control agent and the slow release control agent are required to be printed, and filling the medicinal materials if the quick release control agent and the slow release control agent are not required to be printed.
Preferably, each nozzle stays in a waiting area after printing is completed, and the waiting area is positioned between the initial position of the nozzle and the printing platform. When each spray head alternately prints, the moving distance of the spray head can be reduced, and the printing speed is increased.
Compared with the prior art, the beneficial effects are that: the original mass-produced drug model is used as an original model input to the 3D printer, the data of the auxiliary material layer of the original model is used for corresponding to the fixed release time of the drug, and when the release time of the drug needs to be controlled, the auxiliary material layer in the original model corresponding to the drug is only required to be changed, so that the release time of the drug is controllable. When medicines with different release times are printed, the medicines do not need to be remodelled each time, so that the workload of medicine modeling is reduced, the cost is reduced, and the medicine customization is truly feasible.
Drawings
FIG. 1 is a flow chart of a release time controllable 3D printing pharmaceutical method of the present invention;
FIG. 2 is a schematic structural diagram of an original model of a drug;
FIG. 3 is a schematic diagram of the structure of model one of the drugs with DeltaT 1 greater than zero;
FIG. 4 is a schematic diagram of the structure of model one of the drugs with DeltaT 1 less than zero;
FIG. 5 is a second drug model with T2 less than T1 and T1 less than T;
FIG. 6 is a second drug model with T2 greater than T1 and less than T;
fig. 7 is a drug model three.
Detailed Description
The drawings are for illustrative purposes only and are not to be construed as limiting the present patent; for the purpose of better illustrating the embodiments, certain elements of the drawings may be omitted, enlarged or reduced and do not represent the actual product dimensions; it will be appreciated by those skilled in the art that certain well-known structures in the drawings and descriptions thereof may be omitted. The positional relationship depicted in the drawings is for illustrative purposes only and is not to be construed as limiting the present patent.
The same or similar reference numbers in the drawings of embodiments of the invention correspond to the same or similar components; in the description of the present invention, it should be understood that, if there are orientations or positional relationships indicated by terms "upper", "lower", "left", "right", "long", "short", etc., based on the orientations or positional relationships shown in the drawings, this is merely for convenience in describing the present invention and simplifying the description, and is not an indication or suggestion that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, so that the terms describing the positional relationships in the drawings are merely for exemplary illustration and are not to be construed as limitations of the present patent, and that it is possible for those of ordinary skill in the art to understand the specific meaning of the terms described above according to specific circumstances.
The technical scheme of the invention is further specifically described by the following specific embodiments with reference to the accompanying drawings:
example 1
An embodiment of a 3D printing pharmaceutical method with controllable release time is shown in fig. 1, comprising the steps of:
step one: inputting original models of different medicines into a printer, wherein the original models of the medicines comprise medicinal materials and auxiliary material layers wrapping the medicinal materials; extracting data of an auxiliary material layer in an original model of the medicine, wherein the auxiliary material layer corresponds to the fixed release time of the medicine, and establishing standard release time T of the auxiliary material layer;
step two: setting target release time T1 of the drug X, selecting an auxiliary material layer with the standard release time T of the auxiliary material layer being closest to T1, wherein the difference between the fixed release time T of the drug and the target release time T1 is DeltaT1=T-T1; if DeltaT 1 is larger than zero, generating a plurality of pores with the volume of S on the auxiliary material layer, wherein each pore correspondingly reduces the release time T, and the number of the pores n 1= DeltaT1/T; if DeltaT 1 is smaller than zero, a plurality of slow-release auxiliary material layers with the thickness of C are regenerated outside the auxiliary material layers, the release time T1 is correspondingly increased for each slow-release auxiliary material layer, and the quantity of the slow-release auxiliary material layers is n 1= DeltaT1/T1; and (3) storing the new pharmaceutical model I after the dosage of the medicine is generated in the auxiliary material layer.
After the modeling of the drug model I is completed, the drug model is divided into a plurality of flat layers by adopting a layering printing mode, and then the flat layers are printed layer by layer. Respectively loading the material and the medicinal materials of the auxiliary material layer into different spray heads, printing the auxiliary material layer when each flat layer is printed, and skipping when the positions of the medicinal materials, the quick release control agent and the slow release control agent are needed to be printed; and after printing of the auxiliary material layer of one flat layer, filling the quick release control agent and the slow release control agent if the quick release control agent and the slow release control agent are required to be printed, and filling the medicinal materials if the quick release control agent and the slow release control agent are not required to be printed. And after the printing of each spray head is finished, the spray heads stay in a waiting area, and the waiting area is positioned between the initial position of the spray heads and the printing platform. When each spray head alternately prints, the moving distance of the spray head can be reduced, and the printing speed is increased.
The working principle or workflow of the present embodiment: the original model of the medicine X is shown in fig. 2, the medicine model of the medicine X with delta T1 being larger than zero is shown in fig. 3, the medicine model of the medicine X with delta T being smaller than zero is shown in fig. 4, and in each drawing, the reference numeral 1 is an auxiliary material layer, and the reference numeral 2 is a medicinal material. The original mass-produced drug model is used as an original model input to a 3D printer, and the data of an auxiliary material layer of the original model corresponds to the fixed release time of the drug, so that a database of the standard release time T of the auxiliary material layer is established. When the release time of the drug is required to be controlled and is not the standard release time, selecting an auxiliary material layer reference according to the target release time T1 and modifying parameters of the auxiliary material layer according to the method of the step two. When different medicines are printed to control the release time, the whole medicine is not required to be remodelled, and the medicine model with the release time meeting the target requirement can be obtained by modifying the original model on the basis of an auxiliary material layer, so that the workload of medicine modeling is reduced, and the cost is reduced.
Example 2
In example 2 of the 3D printing pharmaceutical method with controllable release time, based on example 1, the target release time of the drug X is set to be T2 on the basis of example 1, T2 is inconsistent with T1, and a drug model two is generated on the basis of the drug model one. The target release time T2 of the second drug model is set to be one if T2 is smaller than T1 and T1 is smaller than T; if T2 is greater than T1 and less than T, executing second setting;
setting one: based on the auxiliary material layer of the new model I generated in the step two; printing 1 unit of quick release control agent in the pore, wherein the release time T3 is correspondingly reduced per unit of quick release control agent, and the printing amount of the quick release control agent is n2= (T1-T2)/T3;
setting two: based on the auxiliary material layer of the new model I generated in the step two; printing 1 unit of slow release control agent in the pore, wherein the release time T4 is correspondingly increased per unit of slow release control agent, and the printing amount of the slow release control agent is n2= (T2-T1)/T4;
the working principle or workflow of the present embodiment: the original model of the drug X is shown in fig. 2, the drug model II of the drug X with T2 smaller than T1 and T1 smaller than T is shown in fig. 5, wherein 3 is an immediate release control agent, and the drug model II of the drug X with T2 larger than T1 and smaller than T is shown in fig. 6, wherein 4 is a slow release control agent. The release time of the drug is further changed on the basis of the second drug model, since the number of pores that can be formed by the auxiliary layer is limited, since the control of the release time of the drug is achieved by filling the immediate release control agent and the sustained release control agent. And the drug model II adopts a layering printing mode, and the drug model is printed layer by layer after being divided into a plurality of flat layers. Respectively loading the material of the auxiliary material layer, the medicinal material, the quick release control agent and the slow release control agent on different spray heads, printing the auxiliary material layer when each flat layer is printed, and skipping when the positions of the medicinal material, the quick release control agent and the slow release control agent are needed to be printed; and after printing of the auxiliary material layer of one flat layer, filling the quick release control agent and the slow release control agent if the quick release control agent and the slow release control agent are required to be printed, and filling the medicinal materials if the quick release control agent and the slow release control agent are not required to be printed.
The remaining features and operation principle of the present embodiment are the same as those of embodiment 1.
Example 3
Based on the embodiment 2, three sequentially nested auxiliary material layers with sequentially increasing release time are generated according to the step two, and the medicine X is distributed in a cavity between each auxiliary material layer to generate a multi-layer nested medicine model three. Wherein the release time of the auxiliary material layer located at the intermediate position is set to a target release time T0, and the release time of the auxiliary material layer located at the outer layer is set to be shorter than the target release time T0-L, and the release time of the auxiliary material layer located at the inner layer is set to be longer than the target release time t0+l. The drug between each auxiliary material layer can be released intermittently, and the release time of the drug is in the range of 2L so as to cover the target release time T0. Ensuring that the drug is released at the optimal release time point T0. Drug model three is shown in figure 7.
Further, a multi-layer nested drug model IV is generated based on the drug model III. After the medicine model III is stored, when the same medicine printing is needed in the follow-up process but different target release time is needed, the medicine model IV meeting the requirements is built by adopting the method of the step III to change parameters based on the medicine model III, so that the similar medicine printing does not need repeated modeling, and the workload is reduced.
Specifically, cavities between each auxiliary material layer in the third medicine model and the fourth medicine model are filled with the same medicinal materials, and the content of the medicinal materials is equal.
The remaining features and operation principle of the present embodiment are the same as those of embodiment 1.
Example 4
Example 4 of the 3D printing pharmaceutical method with controllable release time is based on example 3 above, which is different in that the cavities between each of the adjuvant layers in the drug model three and the drug model four are filled with different medicinal materials. The tablet can be swallowed to release different medicines at different times, so that the dosage can be reduced.
It is to be understood that the above examples of the present invention are provided by way of illustration only and not by way of limitation of the embodiments of the present invention. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. Any modification, equivalent replacement, improvement, etc. which come within the spirit and principles of the invention are desired to be protected by the following claims.

Claims (10)

1. A release time controllable 3D printing pharmaceutical method, comprising the steps of:
step one: inputting original models of different medicines into a printer, wherein the original models of the medicines comprise medicinal materials and auxiliary material layers wrapping the medicinal materials; extracting data of an auxiliary material layer in an original model of the medicine, wherein the auxiliary material layer corresponds to the fixed release time of the medicine, and establishing standard release time T of the auxiliary material layer;
step two: setting target release time T1 of the drug, selecting an auxiliary material layer with the standard release time T of the auxiliary material layer closest to T1, wherein the difference between the fixed release time T of the drug and the target release time T1 is DeltaT1=T-T1; if DeltaT 1 is larger than zero, generating a plurality of pores with the volume of S on the auxiliary material layer, wherein each pore correspondingly reduces the release time T, and the number of the pores n 1= DeltaT1/T; if DeltaT 1 is smaller than zero, a plurality of slow-release auxiliary material layers with the thickness of C are regenerated outside the auxiliary material layers, the release time T1 is correspondingly increased for each slow-release auxiliary material layer, and the quantity of the slow-release auxiliary material layers is n 1= DeltaT1/T1; and (3) storing the new pharmaceutical model I after the dosage of the medicine is generated in the auxiliary material layer.
2. The method of claim 1, further comprising the step of generating a second drug model based on the first drug model if another target release time T2 of the drug is desired.
3. The method according to claim 2, wherein setting a target release time T2 of the second drug model is performed if T2 is smaller than T1 and T1 is smaller than T; if T2 is greater than T1 and less than T, executing second setting;
setting one: based on the auxiliary material layer of the new model I generated in the step two; printing 1 unit of quick release control agent in the pore, wherein the release time T3 is correspondingly reduced per unit of quick release control agent, and the printing amount of the quick release control agent is n2= (T1-T2)/T3;
setting two: based on the auxiliary material layer of the new model I generated in the step two; in the pores, 1 unit of the release control agent was printed, the release time T4 was increased correspondingly per unit of the release control agent, and the printing amount of the release control agent was n2= (T2-T1)/T4.
4. A 3D printing pharmaceutical method with controllable release time according to claim 3, wherein a plurality of sequentially nested adjuvant layers with sequentially increasing release time are generated according to the second step, and the drug is distributed in a cavity between each of the plurality of sequentially nested adjuvant layers to generate a third multi-layer nested drug model.
5. A release time controllable 3D printing pharmaceutical process according to claim 4, wherein according to step three, a multi-layer nested drug model four is generated on the basis of the drug model three.
6. A controlled release 3D printing process according to claim 4 or 5, wherein the cavities between each of the adjuvant layers in the third and fourth drug models are filled with different drugs.
7. The method according to claim 4 or 5, wherein the cavities between each of the auxiliary material layers in the third and fourth drug models are filled with the same medicinal material and the medicinal materials are equal in content.
8. A release time controllable 3D printing pharmaceutical method according to claim 4 or 5, wherein the drug model is printed layer by layer after being divided into a plurality of flat layers by layer printing.
9. The 3D printing pharmaceutical method with controllable release time according to claim 8, wherein the material of the auxiliary material layer, the medicinal material, the quick release control agent and the slow release control agent are respectively loaded on different spray heads, the printing of the auxiliary material layer is finished when each flat layer is printed, and the positions where the medicinal material, the quick release control agent and the slow release control agent are required to be printed are skipped; and after printing of the auxiliary material layer of one flat layer, filling the quick release control agent and the slow release control agent if the quick release control agent and the slow release control agent are required to be printed, and filling the medicinal materials if the quick release control agent and the slow release control agent are not required to be printed.
10. A controlled release 3D printing process according to claim 9, wherein each of the heads is positioned in a waiting area between the initial position of the head and the printing platform after printing is completed.
CN202111585179.8A 2021-12-22 2021-12-22 3D printing pharmaceutical method with controllable release time Active CN114248434B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111585179.8A CN114248434B (en) 2021-12-22 2021-12-22 3D printing pharmaceutical method with controllable release time

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111585179.8A CN114248434B (en) 2021-12-22 2021-12-22 3D printing pharmaceutical method with controllable release time

Publications (2)

Publication Number Publication Date
CN114248434A CN114248434A (en) 2022-03-29
CN114248434B true CN114248434B (en) 2023-07-21

Family

ID=80796930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111585179.8A Active CN114248434B (en) 2021-12-22 2021-12-22 3D printing pharmaceutical method with controllable release time

Country Status (1)

Country Link
CN (1) CN114248434B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449803A (en) * 2020-04-16 2020-07-28 清华大学 Drug-loaded artificial rectum for transplantation and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100333712C (en) * 2005-06-03 2007-08-29 华中科技大学 Material gradient controlled-release administrating system and its three-dimensional printing-forming preparation method
CN101862230A (en) * 2009-04-17 2010-10-20 华中科技大学同济医学院附属协和医院 Controlled-release multilayer drug-loaded artificial bone and preparation method thereof
US20210196572A1 (en) * 2017-04-28 2021-07-01 Hewlett-Packard Development Company, L.P. Producing erosion-controlled release devices
US10350822B1 (en) * 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
KR20200013170A (en) * 2018-07-20 2020-02-06 주식회사 코아팜바이오 A tablet with controlled drug release structure and a method of manufacturing the same using 3D printing technology

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449803A (en) * 2020-04-16 2020-07-28 清华大学 Drug-loaded artificial rectum for transplantation and preparation method thereof

Also Published As

Publication number Publication date
CN114248434A (en) 2022-03-29

Similar Documents

Publication Publication Date Title
US11065196B2 (en) Process for making controlled release medical implant products
US10350822B1 (en) Dosage forms with desired release profiles and methods of designing and making thereof
Warsi et al. 3D printing methods for pharmaceutical manufacturing: opportunity and challenges
US20190117584A1 (en) Systems and methods of on-demand customized medicament doses by 3d printing
EP2664443A1 (en) Solid freeform fabrication using a plurality of modeling materials
West et al. 3D printing: a case of ZipDose® technology–world's first 3D printing platform to obtain FDA approval for a pharmaceutical product
Agrawal et al. 3D Printing technology in pharmaceuticals and biomedical: a review
US10350055B2 (en) Textured breast implant and methods of making same
CN114248434B (en) 3D printing pharmaceutical method with controllable release time
KR20150078774A (en) Methods and device for making drugs with 3D printing technique
JP6592800B2 (en) System for molding moldings
JP2000280355A (en) Apparatus and method for three-dimensional shaping
Patel et al. 3-D printing technology: The promising future in medicine
Rajora et al. 3D Printing: A Review on the transformation of additive manufacturing
Singh et al. Therapeutic Precision: Unveiling the Potential of 3D Printing in Drug Delivery, Tissue Engineering, and Regenerative Medicine
Vyshnavi et al. 3D printing technology in pharmaceutical science
Prasad et al. 3D PRINTING IN PHARMACEUTICAL PRODUCTS: A REVIEW
Jha et al. Advancements in 3D Printing for Pharmaceutical Research and Development: A Review
Teja et al. A Primer for Pharma Professionals on 3D Printing: Fundamentals and Applications
Soni 3D Printing Technologies for Drug Delivery: A Review
Mendes Additive manufacturing for drug delivery
Taghi THE 3D PRINTING TECHNOLOGY IN PHARMACEUTICAL APPLICATIONS
Smith et al. Clinical Applications of 3D Printed Drug Products
Mika et al. Analysis of applications of additive manufacturing in the production of pharmaceuticals
Bhatia et al. Three-Dimensional Printed Drugs and Related Technology: A Potential Review

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant